2140 POSTER A comparison of lapatinib plus capecitabine versus capecitabine for quality-adjusted survival in metastatic breast cancer (MBC): A QTWiST analysis

B.Sherrill; A.Allshouse; M.M.Amonkar; M.D.Walker; S.H.Stein

首页> 外文期刊>European Journal of Cancer Supplements >2140 POSTER A comparison of lapatinib plus capecitabine versus capecitabine for quality-adjusted survival in metastatic breast cancer (MBC): A QTWiST analysis

【24h】

2140 POSTER A comparison of lapatinib plus capecitabine versus capecitabine for quality-adjusted survival in metastatic breast cancer (MBC): A QTWiST analysis

机译：2140海报拉帕替尼联合卡培他滨与卡培他滨治疗转移性乳腺癌（MBC）质量调整生存率的比较：QTWiST分析

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
B.Sherrill; A.Allshouse; M.M.Amonkar; M.D.Walker; S.H.Stein;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment [J] . X.Zhou, A.Segreti, D.Cella, European Journal of Cancer Supplements . 2008,第7期

机译：拉帕替尼加卡培他滨与单用卡培他滨治疗ErbB2阳性转移性乳腺癌（MBC）–生活质量（QOL）评估
2. Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment [J] . X.Zhou, A.Segreti, D.Cella, European Journal of Cancer Supplements . 2008,第7期

机译：拉帕替尼加卡培他滨与单用卡培他滨治疗ErbB2阳性转移性乳腺癌（MBC）–生活质量（QOL）评估
3. 2135 POSTER Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with ErbB2+ (HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective [J] . T.E.Delea, P.Tappenden, O.Sofrygin, European Journal of Cancer Supplements . 2007,第4期

机译：2135事前对英国（UK）国家卫生署接受过曲妥珠单抗（TZ）治疗的ErbB2 +（HER2 +）转移性乳腺癌（MBC）妇女的拉帕替尼联合卡培他滨（L + C）的成本效益（CE）（NHS）观点
4. Non-toxic approach for treatment of breast cancer and its cutaneous metastasis: Capecitabine (Xeloda™) enhanced photodynamic therapy in a murine tumor model [C] . Sanjay Anand, Anton Denisyuk, Taylor Bullock, Conference on optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy . 2018

机译：治疗乳腺癌及其皮肤转移的无毒方法：卡培他滨（Xeloda™）在小鼠肿瘤模型中增强了光动力治疗
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective exploratory analysis in EMILIA [O] . I. E. Krop, N. U. Lin, K. Blackwell, -1

机译：曲妥珠单抗Emtansine（T-DM1）与拉帕替尼联合卡培他滨治疗HER2阳性转移性乳腺癌和中枢神经系统转移的患者：EMILIA的回顾性探索性分析
7. PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY) [O] . Sofrygin O, Delea T, Tappenden P, 2008

机译：PCN9比例风险（PH）威布尔模型在分析曲妥珠单抗（TZ）耐药性ERBB2 +（HER2 +）转移性乳腺癌（MBC）患儿的无进展生存率（PFS）和总生存率（OS）方面的有效性C）仅卡西他滨（仅C）

2140 POSTER A comparison of lapatinib plus capecitabine versus capecitabine for quality-adjusted survival in metastatic breast cancer (MBC): A QTWiST analysis

著录项

相似文献

相关主题

期刊订阅